Discovery Life Sciences' subsidiary, AllCells®, has expanded its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S. biotechnology hubs, San Francisco Bay and Boston Metropolitan areas, further solidifying its market-leading position and reinforcing its ability to meet the growing demand for CGT products and services worldwide. AllCells is recognized globally as a quality leader, with a 99% deliverability rate and strict adherence to quality standards. With over 3,700 CGT-focused clinical trials ongoing worldwide, the company has invested heavily in expanding collection sites and increasing apheresis capacity to meet phase-appropriate requirements. AllCells has also scaled its donor digital marketing, recruiting, and event-hosting efforts, as well as expanding its experienced project management team to support new and ongoing GMP projects. The company offers tens of thousands of well-characterized, highly engaged, and recallable donors, along with in-house access to comprehensive analytical characterization, including cell biology, genomic, and proteomic capabilities.
According to Danny Zheng, President of AllCells, this expansion is a crucial step towards the company's goal of becoming the most reliable global supplier of CGT solutions, providing customers with a highly characterized supply chain through a single robust and scaled resource as they pursue groundbreaking breakthroughs in the field of CGT.
ubscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!